Kelly Lawrence W & Associates’s Gilead Sciences GILD Stock Holding History

Kelly Lawrence W & Associates’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$842K	Sell	6,044 -250	-4%	-$35K	0.23%	45
2025 Q4	$773K	Hold	6,294	–	–	0.19%	48
2025 Q3	$699K	Hold	6,294	–	–	0.17%	49
2025 Q2	$698K	Sell	6,294 -1,775	-22%	-$189K	0.18%	49
2025 Q1	$904K	Sell	8,069 -600	-7%	-$61.9K	0.22%	43
2024 Q4	$801K	Sell	8,669 -736	-8%	-$66.3K	0.19%	46
2024 Q3	$789K	Sell	9,405 -895	-9%	-$68.3K	0.18%	47
2024 Q2	$707K	Sell	10,300 -98	-0.9%	-$6.54K	0.16%	50
2024 Q1	$762K	Sell	10,398 -633	-6%	-$48.7K	0.17%	48
2023 Q4	$894K	Hold	11,031	–	–	0.21%	46
2023 Q3	$827K	Sell	11,031 -100	-0.9%	-$7.69K	0.22%	45
2023 Q2	$865K	Sell	11,131 -800	-7%	-$63.8K	0.22%	45
2023 Q1	$990K	Buy	11,931 +2,050	+21%	+$170K	0.27%	42
2022 Q4	$848K	Hold	9,881	–	–	0.24%	45
2022 Q3	$610K	Sell	9,881 -1,649	-14%	-$104K	0.17%	51
2022 Q2	$713K	Sell	11,530 -1,400	-11%	-$86.7K	0.2%	48
2022 Q1	$769K	Sell	12,930 -2,275	-15%	-$145K	0.16%	49
2021 Q4	$1.1M	Sell	15,205 -700	-4%	-$48.2K	0.22%	45
2021 Q3	$1.11M	Sell	15,905 -475	-3%	-$33.4K	0.23%	45
2021 Q2	$1.13M	Sell	16,380 -300	-2%	-$20K	0.24%	46
2021 Q1	$1.08M	Buy	16,680 +10,805	+184%	+$697K	0.26%	48
2020 Q4	$342K	Sell	5,875 -15,580	-73%	-$940K	0.14%	47
2020 Q3	$1.35M	Hold	21,455	–	–	0.4%	33
2020 Q2	$1.65M	Hold	21,455	–	–	0.34%	33
2020 Q1	$1.6M	Sell	21,455 -525	-2%	-$36.3K	0.39%	35
2019 Q4	$1.43M	Sell	21,980 -600	-3%	-$39.1K	0.22%	44
2019 Q3	$1.43M	Buy	22,580 +300	+1%	+$19.6K	0.24%	41
2019 Q2	$1.5M	Sell	22,280 -425	-2%	-$28K	0.26%	41
2019 Q1	$1.48M	Hold	22,705	–	–	0.27%	44
2018 Q4	$1.42M	Sell	22,705 -8,000	-26%	-$559K	0.31%	44
2018 Q3	$2.37M	Buy	30,705 +1,100	+4%	+$83.1K	0.39%	40
2018 Q2	$2.1M	Hold	29,605	–	–	0.39%	41
2018 Q1	$2.23M	Hold	29,605	–	–	0.42%	41
2017 Q4	$2.12M	Hold	29,605	–	–	0.39%	44
2017 Q3	$2.4M	Hold	29,605	–	–	0.46%	41
2017 Q2	$2.1M	Sell	29,605 -38,150	-56%	-$2.54M	0.41%	44
2017 Q1	$4.6M	Buy	67,755 +28,305	+72%	+$1.99M	0.95%	38
2016 Q4	$2.83M	Hold	39,450	–	–	0.63%	38
2016 Q3	$3.12M	Hold	39,450	–	–	0.67%	41
2016 Q2	$3.29M	Buy	39,450 +450	+1%	+$39.9K	0.76%	39
2016 Q1	$3.58M	Hold	39,000	–	–	0.9%	35
2015 Q4	$3.95M	Hold	39,000	–	–	0.89%	36
2015 Q3	$3.83M	Hold	39,000	–	–	0.89%	37
2015 Q2	$4.57M	Hold	39,000	–	–	0.91%	37
2015 Q1	$3.83M	Hold	39,000	–	–	0.83%	36
2014 Q4	$3.68M	Buy	39,000 +5,000	+15%	+$517K	0.77%	37
2014 Q3	$3.62M	Hold	34,000	–	–	0.77%	37
2014 Q2	$2.82M	Buy	+34,000	New	+$2.65M	0.6%	39

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Kelly Lawrence W & Associates's GILD Position: Q1 2026 in Review

Kelly Lawrence W & Associates reduced its Gilead Sciences (GILD) stake by 4% in Q1 2026, selling an estimated $35K and leaving 6,044 shares worth $842K. The position accounts for 0.23% of the portfolio, ranked #45.

Kelly Lawrence W & Associates first reported a position in GILD in Q2 2014 and has held it in 48 quarters since. The position peaked at $4.6M in Q1 2017. 2,311 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

Kelly Lawrence W & Associates held 6,044 shares of Gilead Sciences worth $842K as of Q1 2026.
Kelly Lawrence W & Associates sold 250 Gilead Sciences shares in Q1 2026, an estimated $35K.
Gilead Sciences made up 0.23% of Kelly Lawrence W & Associates's portfolio in Q1 2026, its #45 holding.
Kelly Lawrence W & Associates first reported a position in Gilead Sciences in Q2 2014 and has held it in 48 quarters since.
Kelly Lawrence W & Associates's Gilead Sciences position peaked at $4.6M in Q1 2017.
2,311 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Kelly Lawrence W & Associates's 13F filing for Q1 2026, filed 15 May 2026.